Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of “Moderate Buy” by Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $46.2857.

ZBIO has been the subject of a number of analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $52.00 price target on shares of Zenas BioPharma in a research report on Monday, October 27th. Citigroup upped their target price on Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zenas BioPharma in a research note on Thursday, October 30th. Evercore ISI started coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price target on the stock. Finally, Wall Street Zen raised shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Zenas BioPharma Trading Down 19.7%

Shares of NASDAQ:ZBIO opened at $32.59 on Tuesday. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37. Zenas BioPharma has a 12-month low of $5.83 and a 12-month high of $41.50. The business has a 50 day moving average of $32.62 and a two-hundred day moving average of $21.20. The company has a market capitalization of $1.75 billion, a PE ratio of -4.61 and a beta of -1.62.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Activity at Zenas BioPharma

In other Zenas BioPharma news, major shareholder Sr One Capital Management, Llc acquired 126,315 shares of the stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $19.00 per share, with a total value of $2,399,985.00. Following the transaction, the insider owned 1,917,895 shares in the company, valued at $36,440,005. The trade was a 7.05% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hongbo Lu acquired 263,160 shares of the firm’s stock in a transaction on Tuesday, October 7th. The stock was bought at an average price of $19.00 per share, with a total value of $5,000,040.00. Following the purchase, the director directly owned 321,983 shares of the company’s stock, valued at $6,117,677. This represents a 447.38% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 923,035 shares of company stock valued at $17,628,163 over the last ninety days. 16.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Zenas BioPharma

Several hedge funds have recently modified their holdings of the stock. Quarry LP grew its holdings in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the period. Millennium Management LLC acquired a new position in shares of Zenas BioPharma in the 3rd quarter valued at $1,595,000. Bank of America Corp DE grew its stake in shares of Zenas BioPharma by 5.8% during the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock valued at $329,000 after buying an additional 818 shares during the period. Alliancebernstein L.P. grew its stake in shares of Zenas BioPharma by 12.2% during the 3rd quarter. Alliancebernstein L.P. now owns 18,350 shares of the company’s stock valued at $407,000 after buying an additional 1,990 shares during the period. Finally, Creative Planning acquired a new stake in shares of Zenas BioPharma during the 3rd quarter worth $264,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.